Translational governance at the speed of innovation.
STRIDE.AI helps grant agencies, academic medical centres, and healthcare investors decide which biomedical programs are genuinely ready to translate — and which ones still carry unpriced execution risk.
TRI snapshot
Two product pillars. No fake enterprise sprawl.
The architecture stays lean: one Svelte frontend, one worker layer, and a product surface centered on readiness scoring and governance control.
Application evaluation engine
Score clinical, regulatory, IP, technical, and commercial readiness on one structured translational frame.
Portfolio governance platform
Track milestones, missing evidence, and institutional risk after capital has been committed.
Better go / hold / accelerate decisions
Replace subjective binary review with clearer readiness evidence, risk signals, and action paths.
Three initial buyer groups, one shared decision language.
STRIDE.AI is positioned as a translational decision-support system, not a generic project tracker or research note warehouse.
Triage applications without relying only on panel subjectivity.
Standardize readiness scoring, surface risk concentration, and send structured review packets to committees.
Run translational governance without rebuilding every board deck by hand.
Expose missing artifacts, stage-gate gaps, and commercialization blockers across internal portfolios.
See whether governance maturity actually matches the investment story.
Compress translational diligence into a compact view of evidence quality, milestones, and execution risk.
From submission to portfolio governance.
The first real product workflow is simple: evaluate a program, produce a TRI view, send structured decision support, then monitor milestone and governance follow-through after award.